Nathalie Bernard

[Nathalie Bernard @natelea2001]

@waitmaya 32

[CellCarta @CellCarta]

CellCarta and Pillar Biosciences Announce Multi-Year Global Strategic Partnership to Expand Rapid, Decentralized Tumor Profiling for Oncology Clinical Trials.

Read the Full Announcement: https://t.co/JYcwTbHz31

[CellCarta @CellCarta]

We’re excited to announce a strategic collaboration between CellCarta and Lunit to help accelerate AI-enabled digital pathology for translational research, clinical trials, and companion diagnostic programs.

Read more: https://t.co/eST0NhHjjt

#DigitalPathology #CDx

[CellCarta @CellCarta]

Jessica Runyon from CellCarta will be at NextGen Omics Spatial & Data US! Make sure to reach out to her for a meeting!

Excited to discuss how multi-omics come together to advance therapeutic research.

[CellCarta @CellCarta]

PRESS RELEASE: CellCarta's announces an expanded multi-year strategic partnership with Biofidelity, including exclusivity for Aspyre® Lung in clinical trial settings.

Read the full release: https://t.co/8UyaD7H5CO

[CellCarta @CellCarta]

Interested in detecting specific mutations in disease-related pathways? CellCarta offers a range of genomic assays from single genes to multi-mutation panels.

See which mutations our panels detect in EGFR, KRAS, BRAF, FGFR and PI3KCA 👉https://t.co/RJdyDC20eE

[CellCarta @CellCarta]

Happy New Year!

As we reflect on 2025 and look forward to 2026, we wish you all a year of impact, innovation, and meaningful progress in precision medicine.

#CellCarta #PrecisionMedicine

[CellCarta @CellCarta]

From all of us at CellCarta, we wish you a joyful holiday season filled with relaxation. Thank you for your continued partnership in advancing biomarker strategy and therapeutic development. We look forward to achieving new milestones together in the coming year!

[CellCarta @CellCarta]

Are HGRAC applications hindering your clinical trials in China?

Our blog post helps you through the process & highlights how working with the right partner can make it simpler.

Sidestep HGRAC roadblocks: https://t.co/rVvRDcO3eo

#ClinicalTrials #PrecisionMedicine

[Nathalie Bernard @natelea2001]

@Mishi_2210 1050

[Nathalie Bernard @natelea2001]

@ATRightMovies

[Nathalie Bernard @natelea2001]

@demeterium @vinceflibustier Fan de Silo !!

[Nathalie Bernard @natelea2001]

@vinceflibustier J’ai découvert Silo récemment (série AppleTV mais dispo sur Stremio 😉) c’est vraiment top si tu aimes la SF

[CellCarta @CellCarta]

We're looking forward to sharing some of our latest work at the upcoming Society for Immunotherapy of Cancer Annual Meeting.

📍Visit us at Booth 527 to talk to our experts, ask questions, and see how we can support your immunotherapy projects.

📅https://t.co/IX7JVSBZ6Y

[CellCarta @CellCarta]

Our famous "falling blocks" game is on the road with us at #SITC2025 this year!

Stop by Booth 527 to see if you can make it onto the leaderboard! James and our team are happy to share tips on strategy when it comes to both biomarkers and gaming 🎮

📅https://t.co/IX7JVSBZ6Y

[CellCarta @CellCarta]

🧬Did we miss you at #ESMO2025?

Our poster shared validation data for the Biofidelity Aspyre assay, which we elevated to patient management standards for simplified mutational profiling in NSCLC.

Get the full validation report here!👉 https://t.co/VXdcHKC6jg

[CellCarta @CellCarta]

Biomarkers and Precision Medicine US kicks off NEXT WEEK! 🌉

Jill Whitham and Neil O'Kane will be at booth #8, ready to discuss your wins and challenges in your biomarker strategy. Make sure to stop by!

Busy schedule? Book a meeting with the team: https://t.co/TB05c9D3Ti

[CellCarta @CellCarta]

The @American College of Rheumatology meeting kicks off this week, and we are heading to Chicago!

If you’re advancing your biomarker strategy or need support for your clinical projects, book a meeting or say hi to Simone on the conference floor!

https://t.co/dinaAb9r6k

#ACR25

[CellCarta @CellCarta]

🤝Excited to connect at SITC 2025! We'll be at Booth #527.

We are proud to partner with cancer immunotherapy innovators at every stage, from biomarker discovery to late-phase clinical trials.

Visit us to learn how our expertise can support your program goals!

#SITC2025

[CellCarta @CellCarta]

🎯CellCarta is the first CRO to offer oncoReveal™ CDx pan-cancer solid tumor IVD for patient management.
Learn how we can support your trial: https://t.co/yku8xnrUuX

*Visit Pillar Biosciences website for details on regulatory approval: https://t.co/1XnavjpE6N